The strategies used to create and maintain strong pharmaceutical
patent portfolios must evolve with developments in the
pharmaceutical space. These developments include not just
scientific advancements but also requirements and practices of
regulatory bodies, such as the United States Food and Drug
Administration (FDA). This article addresses innovative prosecution
strategies and useful considerations
that may facilitate better agreement between pharmaceutical patent
practice and FDA policy.
Read "Latest Developments in IP Strategies for Pharmaceuticals″
Summer 2022, International Pharmaceutical Industry
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.